Outcomes at Week 12 from three RCTs of sildenafil with and without antifibrotics in advanced IPF
J. Behr (Munich, Germany), S. Nathan (Falls Church, VA, United States of America), S. Harari (Milan, Italy), W. Wuyts (Leuven, Belgium), K. Kirchgaessler (Basel, Switzerland), M. Bengus (Basel, Switzerland), F. Gilberg (Basel, Switzerland), A. Wells (London, United Kingdom)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Behr (Munich, Germany), S. Nathan (Falls Church, VA, United States of America), S. Harari (Milan, Italy), W. Wuyts (Leuven, Belgium), K. Kirchgaessler (Basel, Switzerland), M. Bengus (Basel, Switzerland), F. Gilberg (Basel, Switzerland), A. Wells (London, United Kingdom). Outcomes at Week 12 from three RCTs of sildenafil with and without antifibrotics in advanced IPF. 778
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: